If you think the public, especially pet owners with heartworm positive animals in particular are buying your lame excuse for ceasing production of the heartworm immidicde, you are mistaken. I am not alone in seeing it for what it is, Greed. Understand the need for a corporation to make money but your actions, or more correctly inaction are totally unacceptable. The damage you are doing to the thousands of pets that desperately need that immidicide is unconscionable. Hopefully the news media will be cooperative and expose the true reason for your actions- pure greed! REFERENCE>>>>>>> There are two drugs approved by the U.S. Food and Drug Administration (FDA) for the treatment of heartworm disease in dogs. Both drugs contain arsenic and are effective at killing adult heartworms. Caparsolate Sodium (arsenamide sodium), the older of the two drugs, is injected into a vein. It is not currently manufactured or marketed in the United States. The newer drug, Immiticide (melarsomine hydrochloride), is given by a deep injection into the back muscles to treat dogs with stabilized class 1, 2, and 3 heartworm disease. http://www.fda.gov/downloads/AnimalVeterinary/ResourcesforYou/Anima... So guess who filed an application with the FDA to make Caparsolate Sodium. MERIAL ltd, NADA 006-623 and from what I can tell it was approved in March 2011. Merial had a patent extension on Immiticide that expired 2006. I'm assuming they were granted an additional extension since no other company is manufacturing a generic form. I was told by a doctor that before a patent expires on a widely used drug. The company changes the formula slightly and markets it under a new name. Then the drug reps push it as a new and improved version. Between the shortage and the failed merger with Sanofi it appears Merial has figured a way to control the market for HW treatment once again. Its just my opinion though because Merial would lose a lot of money if a generic of this drug is made and it isn't about the well being of the dogs it is about the almighty dollar.